Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06287229
Status:
RECRUITING
Last Update Posted:
2024-04-12
First Post:
2024-02-23
Brief Title:
Phase IbII Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With RelapsedRefractory RR and Newly Diagnosed B-cell Acute Lymphocytic Leukemia ALL Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomabHCVAD-inotuzumab-blinatumomab
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-02-23
First Submit QC Date:
February 29 2024
Study First Post Date:
2024-03-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-15
Last Update Post Date:
2024-04-12
Last Update Post Date Type:
ACTUAL